Scanning the cell surface proteome of cancer cells and identification of metastasis-associated proteins using a subtractive immunization strategy

Journal of Proteome Research

Volumn 8, Issue 11, 2009, Pages 5048-5059

  Rasmussen, Nicolaj ^a   Ditzel, Henrik J ^a,b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Breast cancer cell lines; CIITA; HLA DR; M 4A4; Metastases; NM 2C5; Subtractive immunization

Indexed keywords

CELL SURFACE PROTEIN; METASTASIS ASSOCIATED PROTEIN; MONOCLONAL ANTIBODY; PROTEOME; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL SURFACE; CONTROLLED STUDY; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; LYMPHOID ORGAN; METASTASIS; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HLA-DR ANTIGENS; IMMUNIZATION; MALE; MICE; MICE, NUDE; MICE, SCID; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASMS; PROTEOME; TISSUE DISTRIBUTION;

MUS;

EID: 70449428638     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr9004635     Document Type: Article

References (52)

1. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell 2000, 100 (1), 57-70.
2. Tlsty, T. D.; Crawford, Y. G.; Holst, C. R.; Fordyce, C. A.; Zhang, J.; McDermott, K.; Kozakiewicz, K.; Gauthier, M. L. Genetic and epigenetic changes in mammary epithelial cells may mimic early events in carcinogenesis. J. Mammary Gland Biol. Neoplasia 2004, 9 (3), 263-274.
3. van Vliet, J.; Oates, N. A.; Whitelaw, E. Epigenetic mechanisms in the context of complex diseases. Cell. Mol. Life Sci. 2007, 64 (12), 1531-1538. (Pubitemid 46954151)
4. Muller, A.; Homey, B.; Soto, H.; Ge, N.; Catron, D.; Buchanan, M. E.; McClanahan, T.; Murphy, E.; Yuan, W.; Wagner, S. N.; Barrera, J. L.; Mohar, A.; Verastegui, E.; Zlotnik, A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410 (6824), 50-56. (Pubitemid 32225831)
5. Simpson, A. J.; Caballero, O. L.; Jungbluth, A.; Chen, Y. T.; Old, L. J. Cancer/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer 2005, 5 (8), 615-625.
6. Bae, S. C.; Lee, Y. H. Phosphorylation, acetylation and ubiquitination: the molecular basis of RUNX regulation. Gene 2006, 366 (1), 58-66. (Pubitemid 43199594)
7. Slamon, D. J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; Baselga, J.; Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344 (11), 783-792. (Pubitemid 32222155)
8. Burger, J. A.; Kipps, T. J. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006, 107 (5), 1761-1767.
9. Ferrara, N.; Hillan, K. J.; Gerber, H. P.; Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discovery 2004, 3 (5), 391-400.
10. Plosker, G. L.; Figgitt, D. P. Rituximab: a review of its use in non- Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003, 63 (8), 803-843
11. Leth-Larsen, R.; Lund, R.; Hansen, H. V.; Laenkholm, A. V.; Tarin, D.; Jensen, O. N.; Ditzel, H. J. Metastasis-related plasma membrane proteins of human breast cancer cells identified by comparative quantitative mass spectrometry. Mol. Cell. Proteomics 2009, 8, 1436-1449.
12. Lund, R.; Leth-Larsen, R.; Jensen, O. N.; Ditzel, H. J. Efficient Isolation and Quantitative Proteomic Analysis of Cancer Cell Plasma Membrane Proteins for Identification of Metastasis- Associated Cell Surface Markers. J. Proteome Res. 2009, 8 (6), 3078-3079.
13. Prokhorova, T. A.; Rigbolt, K. T.; Johansen, P. T.; Henningsen, J.; Kratchmarova, I.; Kassem, M.; Blagoev, B. Stable isotope labeling by amino acids in cell culture (SILAC) and quantitative comparison of the membrane proteomes of self-renewing and differentiating human embryonic stem cells. Mol. Cell. Proteomics 2009, 8 (5), 959-970.
14. Qiu, H.; Wang, Y. Quantitative analysis of surface plasma membrane proteins of primary and metastatic melanoma cells. J. Proteome Res. 2008, 7 (5), 1904-1915.
15. Zhao, Y.; Zhang, W.; Kho, Y.; Zhao, Y. Proteomic analysis of integral plasma membrane proteins. Anal. Chem. 2004, 76 (7), 1817-1823. (Pubitemid 38451494)
16. Williams, C. V.; Stechmann, C. L.; McLoon, S. C. Subtractive immunization techniques for the production of monoclonal antibodies to rare antigens. Biotechniques 1992, 12 (6), 842-847.
17. Brooks, P. C.; Lin, J. M.; French, D. L.; Quigley, J. P. Subtractive immunization yields monoclonal antibodies that specifically inhibit metastasis. J. Cell Biol. 1993, 122 (6), 1351-1359. (Pubitemid 23277303)
18. Trefzer, U.; Rietz, N.; Chen, Y.; Audring, H.; Herberth, G.; Siegel, P.; Reinke, S.; Koniger, P.; Wu, S.; Ma, J.; Liu, Y.; Wang, H.; Sterry, W.; Guo, Y. SM5-1: a new monoclonal antibody which is highly sensitive and specific for melanocytic lesions. Arch. Dermatol. Res. 2000, 292 (12), 583-589. (Pubitemid 32112965)
19. Urquidi, V.; Sloan, D.; Kawai, K.; Agarwal, D.; Woodman, A. C.; Tarin, D.; Goodison, S. Contrasting expression of thrombospondin- 1 and osteopontin correlates with absence or presence of metastatic phenotype in an isogenic model of spontaneous human breast cancer metastasis. Clin. Cancer Res. 2002, 8 (1), 61-74. (Pubitemid 34101460)
20. Campoli, M.; Chang, C. C.; Oldford, S. A.; Edgecombe, A. D.; Drover, S.; Ferrone, S. HLA antigen changes in malignant tumors of mammary epithelial origin: molecular mechanisms and clinical implications. Breast Dis. 2004, 20, 105-125. (Pubitemid 39600451)
21. Altomonte, M.; Fonsatti, E.; Visintin, A.; Maio, M. Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach. Oncogene 2003, 22 (42), 6564-6569. (Pubitemid 37372336)
22. Shi, B.; Vinyals, A.; Alia, P.; Broceno, C.; Chen, F.; Adrover, M.; Gelpi, C.; Price, J. E.; Fabra, A. Differential expression of MHC class II molecules in highly metastatic breast cancer cells is mediated by the regulation of the CIITA transcription. Implication of CIITA in tumor and metastasis development. Int. J. Biochem. Cell Biol. 2006, 38 (4), 544-562.
23. Redondo, M.; Garcia, J.; Villar, E.; Rodrigo, I.; Perea-Milla, E.; Serrano, A.; Morell, M. Major histocompatibility complex status in breast carcinogenesis and relationship to apoptosis. Hum. Pathol. 2003, 34 (12), 1283-1289. (Pubitemid 38018142)
24. Ting, J. P.; Trowsdale, J. Genetic control of MHC class II expression. Cell 2002, 109 (Suppl.), S21-S33.
25. Reith, W.; LeibundGut-Landmann, S.; Waldburger, J. M. Regulation of MHC class II gene expression by the class II transactivator. Nat. Rev. Immunol. 2005, 5 (10), 793-806. (Pubitemid 41400853)
26. Naves, R.; Lennon, A. M.; Barbieri, G.; Reyes, L.; Puga, G.; Salas, L.; Deffrennes, V.; Rosemblatt, M.; Fellous, M.; Charron, D.; Alcaide-Loridan, C.; Bono, M. R. MHC class II-deficient tumor cell lines with a defective expression of the class II transactivator. Int. Immunol. 2002, 14 (5), 481-491.
27. Galfre, G.; Milstein, C. Preparation of monoclonal antibodies: strategies and procedures. Methods Enzymol. 1981, 73 (Pt B), 3-46.
28. Ellison, G.; Klinowska, T.; Westwood, R. F.; Docter, E.; French, T.; Fox, J. C. Further evidence to support the melanocytic origin of MDA-MB-435. Mol. Pathol. 2002, 55 (5), 294-299.
29. Ross, D. T.; Scherf, U.; Eisen, M. B.; Perou, C. M.; Rees, C.; Spellman, P.; Iyer, V.; Jeffrey, S. S.; Van de Rijn, M.; Waltham, M.; Pergamenschikov, A.; Lee, J. C.; Lashkari, D.; Shalon, D.; Myers, T. G.; Weinstein, J. N.; Botstein, D.; Brown, P. O. Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 2000, 24 (3), 227-235.
30. Rae, J. M.; Creighton, C. J.; Meck, J. M.; Haddad, B. R.; Johnson, M. D. MDA-MB-435 cells are derived from M14 melanoma cells - a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res. Treat. 2007, 104 (1), 13-19.
31. Kloppel, G. Tumour biology and histopathology of neuroendocrine tumours. Best Pract. Res., Clin. Endocrinol. Metab. 2007, 21 (1), 15-31.
32. Clinchy, B.; Gazdar, A.; Rabinovsky, R.; Yefenof, E.; Gordon, B.; Vitetta, E. S. The growth and metastasis of human, HER-2/neuoverexpressing tumor cell lines in male SCID mice. Breast Cancer Res. Treat. 2000, 61 (3), 217-228.
33. Harrell, J. C.; Dye, W. W.; Allred, D. C.; Jedlicka, P.; Spoelstra, N. S.; Sartorius, C. A.; Horwitz, K. B. Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. Cancer Res. 2006, 66 (18), 9308-9315.
34. Mobus, V. J.; Moll, R.; Gerharz, C. D.; Kieback, D. G.; Merk, O.; Runnebaum, I. B.; Linner, S.; Dreher, L.; Grill, H. J.; Kreienberg, R. Differential characteristics of two new tumorigenic cell lines of human breast carcinoma origin. Int. J. Cancer 1998, 77 (3), 415-423. (Pubitemid 28299879)
35. Mukhopadhyay, R.; Theriault, R. L.; Price, J. E. Increased levels of alpha6 integrins are associated with the metastatic phenotype of human breast cancer cells. Clin. Exp. Metastasis 1999, 17 (4), 325-332.
36. Price, J. E. Metastasis from human breast cancer cell lines. Breast Cancer Res. Treat. 1996, 39 (1), 93-102. (Pubitemid 26136507)
37. van Slooten, H. J.; Bonsing, B. A.; Hiller, A. J.; Colbern, G. T.; van Dierendonck, J. H.; Cornelisse, C. J.; Smith, H. S. Outgrowth of BT-474 human breast cancer cells in immune-deficient mice: a new in vivo model for hormone-dependent breast cancer. Br. J. Cancer 1995, 72 (1), 22-30.
38. Edidin, M.; Kuo, S. C.; Sheetz, M. P. Lateral movements of membrane glycoproteins restricted by dynamic cytoplasmic barriers. Science 1991, 254 (5036), 1379-1382.
39. Nagy, Z. A.; Hubner, B.; Lohning, C.; Rauchenberger, R.; Reiffert, S.; Thomassen-Wolf, E.; Zahn, S.; Leyer, S.; Schier, E. M.; Zahradnik, A.; Brunner, C.; Lobenwein, K.; Rattel, B.; Stanglmaier, M.; Hallek, M.; Wing, M.; Anderson, S.; Dunn, M.; Kretzschmar, T.; Tesar, M. Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. Nat. Med. 2002, 8 (8), 801-807. (Pubitemid 34887243)
40. Barakat, M. T.; Meeran, K.; Bloom, S. R. Neuroendocrine tumours. Endocr.-Relat. Cancer 2004, 11 (1), 1-18.
41. Lum, S. S.; Fletcher, W. S.; O'Dorisio, M. S.; Nance, R. W.; Pommier, R. F.; Caprara, M. Distribution and functional significance of somatostatin receptors in malignant melanoma. World J. Surg. 2001, 25 (4), 407-412. (Pubitemid 32455189)
42. Taupenot, L.; Harper, K. L.; O'Connor, D. T. The chromogranin- secretogranin family. N. Engl. J. Med. 2003, 348 (12), 1134-1149.
43. Lindblom, A.; Liljegren, A. Regular review: tumour markers in malignancies. BMJ (Br. Med. J.) 2000, 320 (7232), 424-427.
44. Lamberts, S. W.; Hofland, L. J.; Nobels, F. R. Neuroendocrine tumor markers. Front. Neuroendocrinol. 2001, 22 (4), 309-339.
45. Tamiolakisl, D.; Venizelos, I.; Lambropoulou, M.; Jivannakis, T.; Seliniotakis, E.; Tsikouras, P.; Limberis, V.; Tsalkidis, A.; Papadopoulos, N. Gains and losses of HLA class II (DR) and CD4 in atypical hyperplasia, carcinoma in situ and infiltrating ductal carcinoma of the breast. Acta Med. (Hradec Kralove, Czech Repub.) 2004, 47 (4), 257-262.
46. Chamuleau, M. E.; Ossenkoppele, G. J.; van de Loosdrecht, A. A. MHC class II molecules in tumour immunology: prognostic marker and target for immune modulation. Immunobiology 2006, 211 (6-8), 619-625.
47. Shankaran, V.; Ikeda, H.; Bruce, A. T.; White, J. M.; Swanson, P. E.; Old, L. J.; Schreiber, R. D. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410 (6832), 1107-1111.
48. Odum, N.; Kanner, S. B.; Ledbetter, J. A.; Svejgaard, A. MHC class II molecules deliver costimulatory signals in human T cells through a functional linkage with IL-2-receptors. J. Immunol. 1993, 150 (12), 5289-5298.
49. Odum, N.; Ledbetter, J. A.; Martin, P.; Geraghty, D.; Tsu, T.; Hansen, J. A.; Gladstone, P. Homotypic aggregation of human cell lines by HLA class II-, class Ia- and HLA-G-specific monoclonal antibodies. Eur. J. Immunol. 1991, 21 (9), 2121-2131.
50. Goodwin, B. L.; Xi, H.; Tejiram, R.; Eason, D. D.; Ghosh, N.; Wright, K. L.; Nagarajan, U.; Boss, J. M.; Blanck, G. Varying functions of specific major histocompatibility class II transactivator promoter III and IV elements in melanoma cell lines. Cell Growth Differ. 2001, 12 (6), 327-335.
51. Yazawa, T.; Ito, T.; Kamma, H.; Suzuki, T.; Okudela, K.; Hayashi, H.; Horiguchi, H.; Ogata, T.; Mitsui, H.; Ikeda, M.; Kitamura, H. Complicated mechanisms of class II transactivator transcription deficiency in small cell lung cancer and neuroblastoma. Am. J. Pathol. 2002, 161 (1), 291-300.
52. Radosevich, M.; Song, Z.; Gorga, J. C.; Ksander, B.; Ono, S. J. Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHC genes in ocular melanoma cells. Invest. Ophthalmol. Vis. Sci. 2004, 45 (9), 3185-3195.